Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

Similar articles for PubMed (Select 22792655)

1.

Possible prevention and treatment of prostate cancer by exercise.

Zaslau S, Jansen R, Riggs DR, Jackson BJ, Bryner RW.

W V Med J. 2012 May-Jun;108(3):42-7. Review.

PMID:
22792655
2.

Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.

McNaughton-Collins M, Walker-Corkery E, Barry MJ.

J Natl Cancer Inst Monogr. 2004;(33):78-101. Review.

PMID:
15504921
3.

A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial.

Galvão DA, Spry N, Taaffe DR, Denham J, Joseph D, Lamb DS, Levin G, Duchesne G, Newton RU.

BMC Cancer. 2009 Dec 2;9:419. doi: 10.1186/1471-2407-9-419.

4.

Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review.

Keogh JW, MacLeod RD.

J Pain Symptom Manage. 2012 Jan;43(1):96-110. doi: 10.1016/j.jpainsymman.2011.03.006. Epub 2011 Jun 2. Review.

PMID:
21640547
5.

Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.

Galvão DA, Taaffe DR, Spry N, Newton RU.

Prostate Cancer Prostatic Dis. 2007;10(4):340-6. Epub 2007 May 8. Review.

PMID:
17486110
6.

Early prostate cancer: prevention, treatment modalities, and quality of life issues.

Moul JW, Anderson J, Penson DF, Klotz LH, Soloway MS, Schulman CC.

Eur Urol. 2003 Sep;44(3):283-93. Review.

PMID:
12932925
7.

Quality of life and economic considerations in the management of prostate cancer.

Turini M, Redaelli A, Gramegna P, Radice D.

Pharmacoeconomics. 2003;21(8):527-41. Review.

PMID:
12751912
8.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
9.
10.

Complications of androgen deprivation therapy in prostate cancer.

Schwandt A, Garcia JA.

Curr Opin Urol. 2009 May;19(3):322-6. doi: 10.1097/MOU.0b013e32832a082c. Review.

PMID:
19318949
11.

Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.

Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA.

J Clin Oncol. 2003 May 1;21(9):1653-9.

PMID:
12721238
12.

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.

Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review.

13.

Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.

Moinpour CM, Savage MJ, Troxel A, Lovato LC, Eisenberger M, Veith RW, Higgins B, Skeel R, Yee M, Blumenstein BA, Crawford ED, Meyskens FL Jr.

J Natl Cancer Inst. 1998 Oct 21;90(20):1537-44.

14.

A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.

Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW.

BJU Int. 2012 May;109(10):1495-502. doi: 10.1111/j.1464-410X.2011.10555.x. Epub 2011 Sep 20.

PMID:
21933330
15.
16.

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Abrahamsson PA.

Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049. Epub 2009 Aug 7. Review.

PMID:
19683858
17.

Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia.

Maluta S, Dall'oglio S, Nadalini L.

Int J Hyperthermia. 2010;26(8):765-74. doi: 10.3109/02656736.2010.509749.

PMID:
21043571
18.

Antiandrogens in the treatment of prostate cancer.

Wirth MP, Hakenberg OW, Froehner M.

Eur Urol. 2007 Feb;51(2):306-13; discussion 314. Epub 2006 Sep 11. Review.

PMID:
17007995
19.

Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention.

Culos-Reed SN, Robinson JW, Lau H, Stephenson L, Keats M, Norris S, Kline G, Faris P.

Support Care Cancer. 2010 May;18(5):591-9. doi: 10.1007/s00520-009-0694-3. Epub 2009 Jul 16.

PMID:
19609570
20.

Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.

Polascik TJ.

Prostate Cancer Prostatic Dis. 2008;11(1):13-9. Epub 2007 Oct 9. Review.

PMID:
17923854
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk